Catherine R. Sears

Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement

Peter J. Mazzone, Catherine R. Sears, Douglas A. Arenberg et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 134 citations · Full text

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement

Catherine R. Sears, Tobias Peikert, Jennifer D. Possick et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 132 citations · Full text

Assessment of Advanced Diagnostic Bronchoscopy Outcomes for Peripheral Lung Lesions: A Delphi Consensus Definition of Diagnostic Yield and Recommendations for Patient-centered Study Designs. An Official American Thoracic Society/American College of Chest Physicians Research Statement

Anne V. Gonzalez, Gerard A. Silvestri, Daniël A. Korevaar et al. · American Journal of Respiratory and Critical Care Medicine · 2024 · 93 citations · Full text

Complex Cisplatin-Double Strand Break (DSB) Lesions Directly Impair Cellular Non-Homologous End-Joining (NHEJ) Independent of Downstream Damage Response (DDR) Pathways

Catherine R. Sears, John J. Turchi · Journal of Biological Chemistry · 2012 · 64 citations · Full text

Chromatin, Genome Instability, Chromatin Remodeling +7

DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer

Catherine R. Sears, Sean A. Cooney, Helen Chin-Sinex et al. · DNA repair · 2016 · 58 citations

Chromatin, Oncology, Cisplatin Radiosensitization +12